Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $5.63

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $5.63.

Several equities analysts have issued reports on VOR shares. Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Oppenheimer reaffirmed an "outperform" rating and issued a $8.00 price target on shares of Vor Biopharma in a report on Friday, March 21st. Baird R W lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. JMP Securities reaffirmed a "market perform" rating and issued a $6.00 target price on shares of Vor Biopharma in a research note on Friday, May 9th. Finally, Jones Trading lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th.

Vor Biopharma Stock Performance

Shares of NYSE:VOR traded down $0.27 on Friday, hitting $2.40. The stock had a trading volume of 30,755,647 shares, compared to its average volume of 4,552,349. The company has a market capitalization of $299.90 million, a price-to-earnings ratio of -1.45 and a beta of 2.04. Vor Biopharma has a twelve month low of $0.13 and a twelve month high of $3.27. The firm's 50 day moving average price is $0.53 and its 200-day moving average price is $0.87.

Hedge Funds Weigh In On Vor Biopharma

Several large investors have recently bought and sold shares of VOR. RA Capital Management L.P. raised its position in shares of Vor Biopharma by 74.3% during the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock valued at $44,007,000 after acquiring an additional 16,897,159 shares during the last quarter. Lynx1 Capital Management LP bought a new stake in Vor Biopharma in the fourth quarter valued at about $707,000. Jane Street Group LLC acquired a new position in Vor Biopharma in the first quarter valued at about $140,000. Two Sigma Investments LP lifted its stake in Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after buying an additional 25,930 shares during the period. Finally, Northern Trust Corp boosted its holdings in Vor Biopharma by 39.0% during the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after buying an additional 44,252 shares during the last quarter. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.